Compare PHAT & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | FSBW |
|---|---|---|
| Founded | 2018 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.6M | 305.6M |
| IPO Year | 2019 | 2012 |
| Metric | PHAT | FSBW |
|---|---|---|
| Price | $14.60 | $42.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $17.33 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 777.9K | 14.6K |
| Earning Date | 10-30-2025 | 01-20-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.09 |
| Revenue | ★ $147,190,000.00 | $140,954,000.00 |
| Revenue This Year | $218.59 | $10.46 |
| Revenue Next Year | $84.38 | $4.42 |
| P/E Ratio | ★ N/A | $10.43 |
| Revenue Growth | ★ 460.30 | 1.07 |
| 52 Week Low | $2.21 | $34.61 |
| 52 Week High | $16.45 | $46.20 |
| Indicator | PHAT | FSBW |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 68.46 |
| Support Level | $14.12 | $39.48 |
| Resistance Level | $16.27 | $43.24 |
| Average True Range (ATR) | 0.74 | 0.69 |
| MACD | -0.11 | 0.28 |
| Stochastic Oscillator | 23.18 | 94.68 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.